开云app官网登录入口网页版-官方正版

#avacopan#

5篇内容 | 1002人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1461716, encodeId=263c1461e1652, content=<a href='/topic/show?id=5578302189' target=_blank style='color:#2F92EE;'>#avacopan#</a>, objectTitle=NEJM：Avacopan用于治疗ANCA相关性血管炎, objectType=article, longId=207249, objectId=bc5820e249bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc5820e249bc, replyNumber=0, likeNumber=78, createdTime=2021-02-19, rootId=0, userName=医生2396, userId=62456440237, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc5820e249bc, moduleTitle=NEJM：Avacopan用于治疗ANCA相关性血管炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bc5820e249bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461715, encodeId=45a21461e15c6, content=<a href='/topic/show?id=5578302189' target=_blank style='color:#2F92EE;'>#avacopan#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=76, createdTime=2020-10-31, rootId=0, userName=医生2396, userId=62456440237, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461714, encodeId=8b9c1461e14fd, content=<a href='/topic/show?id=5578302189' target=_blank style='color:#2F92EE;'>#avacopan#</a>, objectTitle=FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）, objectType=article, longId=200910, objectId=479020091084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=479020091084, replyNumber=0, likeNumber=73, createdTime=2020-09-20, rootId=0, userName=医生2396, userId=62456440237, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=479020091084, moduleTitle=FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=479020091084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461713, encodeId=906f1461e1393, content=<a href='/topic/show?id=5578302189' target=_blank style='color:#2F92EE;'>#avacopan#</a>, objectTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, objectType=article, longId=183997, objectId=f31218399ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31218399ec7, replyNumber=0, likeNumber=64, createdTime=2019-12-04, rootId=0, userName=医生2396, userId=62456440237, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31218399ec7, moduleTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f31218399ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1461712, encodeId=b4ad1461e1258, content=<a href='/topic/show?id=5578302189' target=_blank style='color:#2F92EE;'>#avacopan#</a>, objectTitle=JASN：C5a受体抑制剂avacopan治疗ANCA相关血管炎的疗效如何？, objectType=article, longId=95627, objectId=a6a99562e43, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6a99562e43, replyNumber=0, likeNumber=64, createdTime=2017-04-14, rootId=0, userName=医生2396, userId=62456440237, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6a99562e43, moduleTitle=JASN：C5a受体抑制剂avacopan治疗ANCA相关血管炎的疗效如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a6a99562e43)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

avacopan

2020-05-29

医生2396 (审核中...)

前往app查看评论内容

#avacopan#

NEJM：Avacopan用于治疗ANCA相关性血管炎

2021-02-19

医生2396 (审核中...)

前往app查看评论内容

#avacopan#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2020-10-31

医生2396 (审核中...)

前往app查看评论内容

#avacopan#

FDA授予Avacopan治疗ANCA相关性血管炎的新药申请（NDA）

2020-09-20

医生2396 (审核中...)

前往app查看评论内容

#avacopan#

ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点

2019-12-04

医生2396 (审核中...)

前往app查看评论内容

#avacopan#

JASN：C5a受体抑制剂avacopan治疗ANCA相关血管炎的疗效如何？

2017-04-14

科室
- - 订阅+
  - 更多科室
工具
服务